Myeloid Leukemia Clinical Trials in Houston, Texas
90 recruitingHouston, Texas
Showing 1–20 of 90 trials
Recruiting
Phase 1
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Taiho Oncology, Inc.27 enrolled22 locationsNCT04953910
Recruiting
Phase 1
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Taiho Oncology, Inc.18 enrolled21 locationsNCT04953897
Recruiting
Phase 1
A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
M.D. Anderson Cancer Center40 enrolled1 locationNCT06191978
Recruiting
Phase 2
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center140 enrolled1 locationNCT06811233
Recruiting
Phase 1Phase 2
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent Acute Myeloid Leukemia+3 more
M.D. Anderson Cancer Center97 enrolled1 locationNCT04140487
Recruiting
Phase 1Phase 2
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Acute Myeloid Leukemia
M.D. Anderson Cancer Center8 enrolled4 locationsNCT06284486
Recruiting
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Head and Neck CarcinomaMalignant Solid NeoplasmSarcoma+59 more
Alliance for Clinical Trials in Oncology2,000 enrolled745 locationsNCT05334069
Recruiting
Phase 1
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Seagen, a wholly owned subsidiary of Pfizer178 enrolled54 locationsNCT04227847
Recruiting
Phase 1
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Gastric CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+1 more
SillaJen, Inc.260 enrolled15 locationsNCT05768932
Recruiting
Phase 1
Phase I Study of HC-7366 for Acute Myeloid Leukemia
Acute Myeloid Leukemia
M.D. Anderson Cancer Center18 enrolled1 locationNCT06285890
Recruiting
Phase 1
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndromes+1 more
Orca Biosystems, Inc.300 enrolled9 locationsNCT03802695
Recruiting
Phase 1
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
Acute Myeloid Leukemia
M.D. Anderson Cancer Center44 enrolled1 locationNCT06769490
Recruiting
Phase 1
Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant
Acute Myeloid Leukemia
Huda Salman30 enrolled4 locationsNCT06197672
Recruiting
Phase 1
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
Acute Myeloid Leukemia
M.D. Anderson Cancer Center125 enrolled1 locationNCT05010772
Recruiting
Phase 1Phase 2
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome+2 more
M.D. Anderson Cancer Center73 enrolled1 locationNCT03661307
Recruiting
Phase 1
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia
M.D. Anderson Cancer Center22 enrolled1 locationNCT06448013
Recruiting
Phase 2
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Acute Myeloid LeukemiaMyeloproliferative NeoplasmBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+4 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT03589729
Recruiting
Early Phase 1
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
Acute Myeloid LeukemiaPediatric AML
Joanna Yi36 enrolled1 locationNCT07059975
Recruiting
Phase 3
Study of Olverembatinib (HQP1351) in Patients With CP-CML
Chronic Myeloid LeukemiaCMLCML, Chronic Phase
Ascentage Pharma Group Inc.285 enrolled1 locationNCT06423911
Recruiting
Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Acute Myeloid Leukemia (AML)
Bio-Path Holdings, Inc.108 enrolled9 locationsNCT02781883